logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article
|
Research

Standards for clinical trials for treating TB

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C,  et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...
Journal Article
|
Protocol

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E,  et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...
Journal Article
|
Research

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults

Furin J, Alirol E, Allen E, Fielding K, Merle CS,  et al.
2016-03-01 • International Journal of Tuberculosis and Lung Disease
2016-03-01 • International Journal of Tuberculosis and Lung Disease
Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in decades, new drugs for the treatment of this disease have been developed. These new dru...
Journal Article
|
Letter

Efficacy, Safety and Tolerability of Linezolid for the Treatment of XDR-TB: a Study in China

Berry C, Yates TA, Seddon JA, Phillips PPJ, du Cros PAK
2016-05-01 • European Respiratory Journal
2016-05-01 • European Respiratory Journal
Journal Article
|
Commentary

Principles for designing future regimens for multidrug-resistant tuberculosis

Brigden G, Nyang'wa BT, du Cros PAK, Varaine FFV, Hughes J,  et al.
2014-01-01 • Bulletin of the World Health Organization
2014-01-01 • Bulletin of the World Health Organization
Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers t...